STROMECTOL (Ivermectin) is a semisynthetic, anthelmintic agent for oral administration. Ivermectin is derived from the avermectins, a class of highly active broad-spectrum, antiparasitic agents isolated from the fermentation products of Streptomyces avermitilis.
Ivermectin is a mixture containing at least 90% 5-Odemethyl-22,23-dihydroavermectin A1a and less than 10% 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro25-(1-methylethyl)avermectin A1a, generally referred to as 22,23-dihydroavermectin B1a and B1b, or H2B1a and H2B1b, respectively
The U.S. FDA approves ivermectin tablets to treat people with intestinal strongyloidiasis and onchocerciasis, two conditions caused by parasitic worms. In addition, some topical forms of Ivermectin are approved to treat external parasites like head lice and for skin conditions such as rosacea.
Ivermectin is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract. Ivermectin is indicated for treating intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis. This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of Ivermectin. In addition, Ivermectin is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus.
Ivermectin Use Against COVID-19
Ivermectin is not authorized or approved by the U.S. FDA for the prevention or treatment of COVID-19. In addition, the U.S. National Institutes of Health's COVID-19 Treatment Guidelines Panel has also determined that there are currently insufficient data to recommend Ivermectin for the treatment of COVID-19.
On October 19, 2021, the Canadian government issued a notice saying, 'Ivermectin not authorized to prevent or treat COVID-19 and may cause serious health problems.'
October 20, 2021 - The NEJM published a Correspondence: Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19. Cases in Oregon illustrate the potentially toxic effects of Ivermectin, including severe episodes of confusion, ataxia, seizures, and hypotension, and the increasing frequency of inappropriate use. In addition, there is insufficient evidence to support the use of Ivermectin to treat or prevent Covid-19, and improper use, as well as the possible occurrence of medication interactions, may result in serious side effects requiring hospitalization.
October 18, 2021 - The Lancet Infectious Diseases published: Long-term consequences of the misuse of ivermectin data.
September 24, 2021 - The Indian Council of Medical Research dropped Ivermectin from the approved COVID-19 treatment protocol.
September 9, 2021 - In an episode of "AMA COVID-19 Update," Dr. Farley discussed the drug's safety concerns, its potential side effects, and the vital role of physicians in guiding the unvaccinated to better choices.
September 3, 2021 - The U.S. FDA published: Why You Should Not Use Ivermectin to Treat or Prevent COVID-19.
August 26, 2021 - The U.S. CDC issued a Health Advisory stating: Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19.
August 24, 2021 - Oregon Poison Center at OHSU experiences a substantial increase in calls involving intentional misuse of Ivermectin.
May 10, 2015 - The Nobel Assembly at Karolinska Institutet has today decided to award the 2015 Nobel Prize in Physiology or Medicine with one-half jointly to William C. Campbell and Satoshi Ōmura for their discoveries concerning a novel therapy against infections caused by roundworm parasites.
Ivermectin Clinical Trials
Ivermectin (Stromectol, Mectizan) has been tested in over 190 clinical trials, including 78 studies using Ivermectin to treat COVID-19.